325. Targeted Gene Addition Strategies for the Treatment of X-Linked Lymphoproliferative Disease

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33134-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

X-Linked Lymphoproliferative Disease (XLP)

English

223. Lentiviral Vector Mediated Gene Therapy for X-Linked Lymphoproliferative Disease Restores Humoral and Cellular Functions

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

121. Targeted Gene Therapy in the Treatment of X-Linked Hyper IgM Syndrome

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Recent Tau-Targeted Clinical Strategies for the Treatment of Alzheimer's Disease

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2019English

Gene Therapy for X-Linked Chronic Granulomatous Disease (Net4CGD)

Human gene therapy. Clinical development
Genetics
2015English

A Rapid Flow Cytometric Screening Test for X-Linked Lymphoproliferative Disease Due to XIAP Deficiency

Cytometry Part B - Clinical Cytometry
Forensic MedicinePathologyHistologyCell Biology
2009English

Phenotypic Differences Between Mice Deficient in XIAP and SAP, Two Factors Targeted in X-Linked Lymphoproliferative Syndrome (XLP)

Cellular Immunology
Immunology
2009English

288. Dual-Regulated Lentiviral Vector for Gene Therapy of X-Linked Chronic Granulomatous Disease

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Targeted Disruption of Dkc1, the Gene Mutated in X-Linked Dyskeratosis Congenita, Causes Embryonic Lethality in Mice

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy